Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons

ACS Chemical Biology

Volumn 6, Issue 10, 2011, Pages 1021-1028

  Ramsden, Nigel ^b   Perrin, Jessica ^a   Ren, Zhao ^c   Lee, Byoung Dae ^d   Zinn, Nico ^a   Dawson, Valina L ^d   Tam, Danny ^c   Bova, Michael ^c   Lang, Manja ^a   Drewes, Gerard ^a   Bantscheff, Marcus ^a   Bard, Frederique ^c   Dawson, Ted M ^d   Hopf, Carsten ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Cellzome Ltd   (United Kingdom)

^c ELAN PHARMACEUTICALS   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CZC 25146; CZC 54252; ENHANCED GREEN FLUORESCENT PROTEIN; ENZYME INHIBITOR; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; EMBRYO; ENZYME INHIBITION; FETUS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NERVE CELL; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEOMICS;

ANIMALS; CELLS, CULTURED; DRUG DESIGN; HUMANS; MUTATION; NEURONS; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; RATS;

RODENTIA;

EID: 80054977424     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb2002413     Document Type: Article

References (30)

1. Gasser, T. (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies Exp. Rev. Mol. Med. 11, e22
2. Cookson, M. R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease Nat. Rev. Neurosci. 11 (12) 791-7
3. Anand, V. S. and Braithwaite, S. P. (2009) LRRK2 in Parkinson's disease: biochemical functions FEBS J. 276 (22) 6428-35
4. Lin, X., Parisiadou, L., Gu, X. L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C. X., Yang, W. J., Ding, J., Chen, Z. Z., Gallant, P. E., Tao-Cheng, J. H., Rudow, G., Troncoso, J. C., Liu, Z., Li, Z., and Cai, H. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein Neuron 64 (6) 807-27
5. Anand, V. S., Reichling, L. J., Lipinski, K., Stochaj, W., Duan, W., Kelleher, K., Pungaliya, P., Brown, E. L., Reinhart, P. H., Somberg, R., Hirst, W. D., Riddle, S. M., and Braithwaite, S. P. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays FEBS J. 276 (2) 466-78
6. Drewes, G., Hopf, C., and Reader, V. Methods for the identification of LRRK2 interacting molecules and for the purification of LRRK2. U.S. Patent US2009220992, 2009.
7. Lee, B. D., Shin, J. H., Vankampen, J., Petrucelli, L., West, A. B., Ko, H. S., Lee, Y. I., Maguire-Zeiss, K. A., Bowers, W. J., Federoff, H. J., Dawson, V. L., and Dawson, T. M. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease Nat. Med. 16, 998-1000
8. Liu, M., Dobson, B., Glicksman, M. A., Yue, Z., and Stein, R. L. (2010) Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities Biochemistry 49 (9) 2008-17
9. Chen, H. M., Wang, L., and D'Mello, S. R. (2008) Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074 J. Neurochem. 105 (4) 1300-12 (Pubitemid 351590789)
10. Li, M., Smith, C. J., Walker, M. T., and Smith, T. J. (2009) Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics J. Biol. Chem. 284 (34) 22988-3000
11. Arita, M., Wakita, T., and Shimizu, H. (2008) Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity J. Gen. Virol. 89 (Pt 10) 2518-30
12. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., and Gray, N. S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 (4) 203-5
13. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 (9) 1035-44 (Pubitemid 47517638)
14. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A. M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dumpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N. G., and Drewes, G. (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 29 (3) 255-65
15. Kruse, U., Pallasch, C. P., Bantscheff, M., Eberhard, D., Frenzel, L., Ghidelli, S., Maier, S. K., Werner, T., Wendtner, C. M., and Drewes, G. (2010) Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells Leukemia 25 (1) 89-100
16. Savitski, M. M., Fischer, F., Mathieson, T., Sweetman, G., Lang, M., and Bantscheff, M. (2010) Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays J. Am. Soc. Mass Spectrom. 21, 1668-79
17. Maekawa, T., Kubo, M., Yokoyama, I., Ohta, E., and Obata, F. (2010) Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen Biochem. Biophys. Res. Commun. 392 (3) 431-5
18. Olaharski, A. J., Gonzaludo, N., Bitter, H., Goldstein, D., Kirchner, S., Uppal, H., and Kolaja, K. (2009) Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors PLoS Comput. Biol. 5 (7) e1000446
19. Olaharski, A. J., Bitter, H., Gonzaludo, N., Kondru, R., Goldstein, D. M., Zabka, T. S., Lin, H., Singer, T., and Kolaja, K. (2010) Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors Toxicol. Sci. 118 (1) 266-75
20. Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9 (10) 1231-3 (Pubitemid 44454261)
21. Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration Proc. Natl. Acad. Sci. U.S.A. 102 (51) 18676-81 (Pubitemid 43011285)
22. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology Neuron 52 (4) 587-93 (Pubitemid 44781171)
23. Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Boyle, F. T., Hewitt, N., Plant, H., and Hedge, P. (1999) Paradoxical activation of Raf by a novel Raf inhibitor Chem. Bio.l 6 (8) 559-68 (Pubitemid 29380770)
24. Van Gompel, J. J., Kunnimalaiyaan, M., Holen, K., and Chen, H. (2005) ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells Mol. Cancer Ther. 4 (6) 910-7 (Pubitemid 40909073)
25. Westerlund, M., Belin, A. C., Anvret, A., Bickford, P., Olson, L., and Galter, D. (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease Neuroscience 152 (2) 429-36
26. Van Limbergen, J., Wilson, D. C., and Satsangi, J. (2009) The genetics of Crohn's disease Annu. Rev. Genomics Hum. Genet. 10, 89-116
27. Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J., and Podolsky, D. K. (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens J. Immunol. 185 (9) 5577-85
28. Pan, S., Aebersold, R., Chen, R., Rush, J., Goodlett, D. R., McIntosh, M. W., Zhang, J., and Brentnall, T. A. (2009) Mass spectrometry based targeted protein quantification: methods and applications J. Proteome Res. 8 (2) 787-97
29. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Keri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 6 (10) 741-4
30. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. U.S.A. 102 (46) 16842-7 (Pubitemid 41688864)